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Objectives: In 2009, Greece entered into one of the most serious economic down-
turns in its modern history. In May 2010, the country was put under the supervi-
sion of Troika (EU, ECB and IMF). Retail pharmaceutical market with size c. a. € 6.5 
bn in retail prices for 2009 (public pharmaceutical expenditure € 5.2 bn), was one 
of the main targets for change through the implementation of new policies and 
drastic spending cuts. The purpose of this study was to measure the impact that 
these new policies for pharmaceutical spending had and how this was attributed 
to the levers of price, market volume and product mix. MethOds: An economic 
model was used, based on IMS Hellas’ and Hellenic Statistical Authority data, 
to measure the contribution that (a) price; (b) market volume; and (c) product 
mix had on the reduction in the size of the retail market for pharmaceuticals in 
the period 2009-2014. The detailed approach decomposes the market change, as 
measured in values, into those attributed to (a) price (assuming market volume 
and product mix are constant); (b) market volume (assuming prices and product 
mix are unchanged); (c) product mix. Results: The analysis indicated that, the 
major contributor in the reduction of the pharmaceutical market size was the 
price of medicines. It has been estimated that 87% of the reduction (> € 1.2 bn) is 
coming from price. Volume contributed an additional c. a. 38% (> € 0.5 bn) in the 
reduction of the size but, at the same time, it was partially offset from substitu-
tion with pricier medicines. cOnclusiOns: Price was the major driver for the 
reduction in the size of the retail pharmaceutical market during the period of 
crisis. Volume had an impact as well but it was partially offset by switch towards 
more expensive medicines.
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Objectives: The “liste-en-sus” was implemented within the framework 
of the HPST [1] law. One of its objectives was to ensure access to highly-priced 
innovative medicines in hospital settings without distorting the Diagnostic-
Related Groups (DRG). The objective of this research is to analyse the degree of 
innovation of the medicines included in the “liste-en-sus”. MethOds: Starting 
from the ATIH [2] database, an initial analysis consisted of identifying all the 
Health Technology Assessments (HTAs) for each product included in the “liste-
en-sus” available on the HAS website [3] . Then, for each HTA, the following infor-
mation was collected: assessment date, SMR [4] and ASMR [5] scores. Results: 
The liste-en sus includes 123 medicines. 21% have no HTA available. Another 19% 
were last evaluated before 2004. Among the medicines which had undergone an 
HTA since 2004, 7% were granted an ASMR I, 27% an ASMR II, 22% an ASMR III, 
8% an ASMR IV, 36% an ASMR V. In other terms, amongst the medicines which 
have undergone an HTA in the last 10 years, about 45% of them were deemed 
non-innovative (ASMR IV/V). Those medicines mainly consist in antihemorrhagics 
(27%), antianaemics (18%), antineoplastics (15%) and immune sera and immuno-
globulins (15%)[6] . Although they are not innovative, those medicines are only 
used in a proportion of patients and are thus likely to distort DRG. To put these 
results into perspective, since 2005, 92% of evaluated medicines were granted an 
ASMR IV/V [7]. cOnclusiOns: Looking at the list-en-sus’ objectives, the most 
decisive criterion seems to be more stability of the DRG rather than access to 
innovative medicines; however a higher proportion of the medicines in the liste-
en-sus are innovative.
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Objectives: To establish the key policy areas that will drive the establishment 
of a sustainable biosimilar medicines market. To outline the benefits that these 
will bring to Physicians, Payers, Patients, and Industry, with particular focus 
on the benefits for European National Health systems. MethOds: 71 qualita-
tive in-depth interviews were conducted across 7 European markets: France, 
Germany, Hungary, Italy, Poland, Spain and the UK, collecting insight from 
experts and policy influencers at pan-European, National and Regional levels, 
Physicians, Payers, Pharmacists, Patients, and Industry. Quantitative modelling 
used a systems dynamics approach with in-depth analysis of 3 representative 
biologic products: trastuzumab, bevacizumab, and adalimumab. Dynamics were 
based on a delphi panel of expert opinions. The five forces of supplier power, buyer 
power, impact of new entrants, impact of substitutes, and competitive rivalry 
were addressed. A ranking of the attractiveness of policy combinations from a 
sustainability and benefit perspective was made based on a biosimilar medicines 
market “Sustainability Index” and the calculation of the magnitude of the ben-
efits (cost savings, additional patients treated) that the policy combination was 
likely to produce. Results: The qualitative analysis has shown that a European 
biosimilars medicines market based on stakeholder and policy alignment in four 
key areas (1. education and understanding, 2. experience and use, 3. sustainable 
pricing, 4. rational decision making) will be sustainable and deliver benefits to 
all stakeholders. The quantitative analysis demonstrated that the most efficient 
policy combination, measured in terms of the sustainability index, was the same 
for all 3 molecules and would deliver cumulative 10 year cost savings of between 
24% and 26%. cOnclusiOns: Greater stakeholder alignment and the combina-
tion of specific policies will increase the sustainability of the European biosimilar 
medicines market. A sustainable biosimilar medicines market will deliver signifi-
cant benefits to all stakeholders.
security funding law, France is becoming the first country to allow biosimilars sub-
stitution when initiating treatment course. To encourage biosimilars substitution, 
the Norwegian Medicines Agency announced in 2013 the funding of clinical studies 
with infliximab originator and biosimilars in which patients would be switched 
from originator to biosimilars forth and back. Moreover, increased price discounts 
of about 40% were applied for infliximab in Norway. By 2020, expected savings 
for biosimilars are estimated around € 12-33 billion in big EU5, Poland, Romania, 
Sweden. cOnclusiOns: While patent cliff of major biologic drugs is expected on 
the next 5 years, initiatives to reassure physicians to prescribe biosimilars and 
implementation of substitution rules, even if still raising some reluctance, might 
contribute to boost biosimilar uptake in Europe. Price competition will impose 
manufacturers of branded biologics to adopt new pricing strategies.
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Objectives: In Turkey, a medicine reference pricing system has been in use since 
2004. The price of pharmaceuticals is determined by the acceptance of the lowest 
ex-factory price in the reference countries (Greece, France, Italy, Portugal, Spain). We 
aimed to examine the first 100 medicine’s, having the annual maximum amount 
on the average Turkish Lira (TL) based medicine sales between the years 2008-2013 
which have 25.1% value in the total pharmaceutical market, reference price changes 
in these period. MethOds: While pharmaceutical sales data were obtained from 
the IMS Health-Turkey data base, medicine prices were obtained from the Medicine 
Price List published by Turkish Medicines and Medical Devices Agency. Results: In 
2008, the top 100 medicines in determining the price of most of Italy were taken as 
the reference country, followed by Spain and Greece. In 2013 while Greece is taken as 
the reference country more common; France and Italy are to follow. In 2008, only one 
medicine’s price increased, and only one medicine’s price decreased because of the 
reference price. In 2009 and 2010 price increases did not seen. In 2009, 8 and in 2010, 
30 medicines prices had decreased. In 2011, 2012 and 2013 totally 27 medicines refer-
ence prices had increased. 21 medicine’s price in 2011, 20 medicine’s price in 2012 
and 24 medicine’s price in 2013 had decreased. While mostly France (13 medicines) 
connected to the reference price increases, mostly Greece (58 medicines) has been 
based reference price drop in the analyzed period. cOnclusiOns: The application 
of reference prices, medicine prices to be reduced to a large extent. Greece based 
reference price decreases are observed to be mainly from the year 2010. The reason 
for this is considered as the economic crisis in Greece and the agreement with the 
IMF, EU and ECB, the Greek government at cost-containment.
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Objectives: External price referencing (EPR) is a method to control pharmaceutical 
prices, wherein decision-makers specify a basket of countries, whose prices they 
use to inform their national target price. EPR is practiced frequently worldwide, 
though countries vary substantially in how they execute EPR. The objective of our 
pioneer collaborative health policy research initiative was to analyse how EPR is 
used in Middle East countries, and assess whether EPR results in narrower price cor-
ridor for innovative pharmaceuticals compared to non-pharmaceutical services not 
subjected to EPR. MethOds: In Q1 2014, we conducted a survey on EPR regulations, 
and collected prices of 16 innovative pharmaceuticals and 10 non-pharmaceutical 
services in six Middle East countries (Egypt, Jordan, Kuwait, Lebanon, Saudi Arabia, 
UAE). Prices in local currency were converted to USD by using market exchange 
rates. Maximum and minimum prices of each pharmaceutical and non-pharmaceu-
tical technology were compared to mean prices in the study countries. Results: 
EPR regulations are most stringent in Egypt and Saudi Arabia (largest study coun-
tries), mandating the lowest pharmaceutical price out of a basket comprising more 
than 25 countries each. By contrast, Kuwait references the country of origin only. The 
average price corridor is +/-38% for pharmaceuticals and +/-78% for outpatient and 
hospital services compared to mean prices. cOnclusiOns: EPR results in narrower 
price corridor for innovative pharmaceuticals compared to other health care ser-
vices. Prices of innovative pharmaceuticals are the lowest in Egypt and Saudi Arabia, 
and the highest in Kuwait, indicating the importance of population size and EPR 
implementation on drug price levels. However, EPR results in higher pharmaceutical 
prices in lower income countries compared to non-pharmaceutical services, which 
may limit timely access of patients to new medicines in these countries compared 
to global markets. Stakeholders should understand the implications of EPR and 
develop solutions to prevent its negative consequences.
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